ZYDUSLIFE2023-10-012023-12-31 ZYDUSLIFE2023-10-012023-12-31 ZYDUSLIFE2023-10-012023-12-31in-bse-fin:OneOperatingExpenses01Member ZYDUSLIFE2023-10-012023-12-31in-bse-fin:OneOperatingExpenses02Member ZYDUSLIFE2023-10-012023-12-31in-bse-fin:FourOperatingExpenses01Member ZYDUSLIFE2023-10-012023-12-31in-bse-fin:FourOperatingExpenses02Member ZYDUSLIFE2023-12-31 ZYDUSLIFE2023-10-012023-12-31in-bse-fin:OneReportableSegmentRevenue01Member ZYDUSLIFE2023-10-012023-12-31in-bse-fin:OneReportableSegmentRevenue02Member ZYDUSLIFE2023-10-012023-12-31in-bse-fin:FourReportableSegmentRevenue01Member ZYDUSLIFE2023-10-012023-12-31in-bse-fin:FourReportableSegmentRevenue02Member ZYDUSLIFE2023-10-012023-12-31in-bse-fin:OneReportableSegmentResults01Member ZYDUSLIFE2023-10-012023-12-31in-bse-fin:OneReportableSegmentResults02Member ZYDUSLIFE2023-10-012023-12-31in-bse-fin:FourReportableSegmentResults01Member ZYDUSLIFE2023-10-012023-12-31in-bse-fin:FourReportableSegmentResults02Member ZYDUSLIFE2023-10-012023-12-31in-bse-fin:OneReportableSegmentAssets01Member ZYDUSLIFE2023-10-012023-12-31in-bse-fin:OneReportableSegmentAssets02Member ZYDUSLIFE2023-10-012023-12-31in-bse-fin:OneReportableSegmentLiabilities01Member ZYDUSLIFE2023-12-31in-bse-fin:OneReportableSegmentLiabilities01Member ZYDUSLIFE2023-10-012023-12-31in-bse-fin:OneReportableSegmentLiabilities02Member ZYDUSLIFE2023-12-31in-bse-fin:OneReportableSegmentLiabilities02Member ZYDUSLIFE2023-10-012023-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ZYDUSLIFE2023-10-012023-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member ZYDUSLIFE2023-10-012023-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss03Member ZYDUSLIFE2023-10-012023-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ZYDUSLIFE2023-10-012023-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss02Member ZYDUSLIFE2023-10-012023-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss03Member ZYDUSLIFE2023-10-012023-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member ZYDUSLIFE2023-10-012023-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532321 ZYDUSLIFE NOTLISTED Zydus Lifesciences Limited Equity 2023-04-01 2024-03-31 2024-02-09 2024-01-29 INR Millions Third quarter 11:05:00 12:45:00 2024-02-09 2024-02-09 Not applicable Multi segment 2023-10-01 2023-12-31 Unaudited Consolidated 45052000000.00 377000000.00 45429000000.00 10632000000.00 4594000000.00 -541000000.00 8173000000.00 198000000.00 1948000000.00 11170000000.00 36174000000.00 9255000000.00 0.00 9255000000.00 1497000000.00 641000000.00 2138000000.00 0.00 7117000000.00 277000000.00 59000000.00 218000000.00 564000000.00 7899000000.00 203000000.00 8102000000.00 7896000000.00 3000000.00 8099000000.00 3000000.00 1012000000.00 1 7.59 7.59 0.21 0.21 7.80 7.80 Multi segment 2023-04-01 2023-12-31 Unaudited Consolidated 140136000000.00 1277000000.00 141413000000.00 33702000000.00 13550000000.00 -1085000000.00 23006000000.00 466000000.00 5588000000.00 33425000000.00 108652000000.00 32761000000.00 -142000000.00 32619000000.00 10277000000.00 -3714000000.00 6563000000.00 0.00 26056000000.00 251000000.00 53000000.00 198000000.00 1013000000.00 27267000000.00 -296000000.00 26971000000.00 26772000000.00 495000000.00 26476000000.00 495000000.00 1012000000.00 1 26.25 26.25 0.20 0.20 26.45 26.45 Net Loss/ (Gain) on foreign currency transactions -206000000.00 Other expenses 11376000000.00 Net Loss/ (Gain) on foreign currency transactions -757000000.00 Other expenses 34182000000.00 Consumer Products 3999000000.00 Pharmaceuticals 41053000000.00 Consumer Products 15324000000.00 Pharmaceuticals 124812000000.00 45052000000.00 140136000000.00 45052000000.00 140136000000.00 Consumer Products 37000000.00 Pharmaceuticals 9218000000.00 Consumer Products 1199000000.00 Pharmaceuticals 31562000000.00 9255000000.00 32761000000.00 9255000000.00 32761000000.00 Consumer Products 58213000000.00 Pharmaceuticals 226016000000.00 284229000000.00 Consumer Products 4352000000.00 Pharmaceuticals 62367000000.00 66719000000.00 Re-measurement gains/ (losses) on post employment defined benefit plans -65000000.00 Net gain/ (loss) on Fair Value through OCI Equity Securities 54000000.00 Share of OCI of joint ventures (net of tax) -1000000.00 Re-measurement gains/ (losses) on post employment defined benefit plans -187000000.00 Net gain/ (loss) on Fair Value through OCI Equity Securities -30000000.00 Share of OCI of joint ventures (net of tax) -1000000.00 -12000000.00 -218000000.00 -13000000.00 -37000000.00 Exchange differences on translation of foreign operations 202000000.00 Exchange differences on translation of foreign operations -115000000.00 202000000.00 -115000000.00 0.00 0.00